Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA

Keyphrases

• Plasma Samples 100%
• Truncating mutation 100%
• Acquired Resistance 100%
• Plasma DNA 100%
• Clonal Evolution 100%
• Genomic Evolution 100%
• Resistance to Cancer Therapy 100%
• Circulating Tumor DNA (ctDNA) 100%
• Allele Fraction 100%
• Non-invasive Analysis 100%
• Paclitaxel 50%
• Splicing mutation 50%
• Cancer Cells 50%
• Human Cancer 50%
• Resistance mutations 50%
• Genetic Modification 50%
• Massively Parallel Sequencing 50%
• Tumor Genome 50%
• Exome Sequencing 50%
• Cisplatin 50%
• Repeat Biopsy 50%
• PIK3CA 50%
• Systemic Treatment 50%
• Tumor Heterogeneity 50%
• Treatment Course 50%
• Response to Therapy 50%
• Acquired Drug Resistance 50%
• Activating mutation 50%
• Metastatic Cancer 50%
• Solid Cancer 50%
• Advanced Cancer 50%
• Cancer Genome 50%
• Exome 50%
• Growth Arrest-specific Gene 6 (Gas6) 50%
• Multiple Courses 50%
• EGFR mutation 50%
• Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC) 50%
• Advanced Ovarian Cancer 50%
• Trastuzumab 50%
• Tumor-derived Exosomes 50%
• Retinoblastoma 1 50%
• Therapy Resistance 50%
• Tumor mutation Burden 50%
• Advanced Breast Cancer 50%
• T790M 50%
• Clonal Selection 50%
• Gefitinib 50%
• Subsequent Therapy 50%
• Mutant Allele 50%
• Breast/ovarian Cancer 50%
• Serial Analysis 50%
• Non-invasive Liquid Biopsy 50%
• Phosphatidylinositol 4-kinase (PI4K) 50%
• Sensitivity Increase 50%
• Lapatinib 50%
• 5-bisphosphate 3-kinase Catalytic Subunit α 50%
• MED1 50%
• Mediator Subunit 50%

Medicine and Dentistry

• Allele 100%
• Cancer 100%
• Cancer Therapy 100%
• Biopsy Technique 100%
• Malignant Neoplasm 66%
• Epidermal Growth Factor Receptor 66%
• Exome 66%
• Circulating Tumor DNA 66%
• Genomic Evolution 66%
• Tumor 66%
• Metastatic Carcinoma 33%
• Breast Cancer 33%
• Cancer Cell 33%
• Drug Resistance 33%
• Lung Cancer 33%
• Growth Disorder 33%
• Systemic Therapy 33%
• Paclitaxel 33%
• Tumour Heterogeneity 33%
• Exome Sequencing 33%
• Liquid Biopsy 33%
• Cisplatin 33%
• Enzyme Active Site 33%
• Retinoblastoma 33%
• Tamoxifen 33%
• Advanced Cancer 33%
• Therapy Resistance 33%
• Alpha Chain 33%
• Trastuzumab 33%
• Gefitinib 33%
• Genetics 33%
• Lapatinib 33%
• Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 33%
• Peroxisome Proliferator Activated Receptor Binding Protein 33%

Biochemistry, Genetics and Molecular Biology

• Blood Plasma 100%
• Allele 37%
• Genomics 37%
• Epidermal Growth Factor Receptor 25%
• Exome 25%
• Clonal Evolution 25%
• Cancer Cell 12%
• Drug Resistance 12%
• Deep Sequencing 12%
• Exome Sequencing 12%
• Cisplatin 12%
• Enzyme Active Site 12%
• Retinoblastoma 12%
• Alpha Chain 12%
• Trastuzumab 12%
• Circulating Tumor DNA 12%
• Gefitinib 12%
• Lapatinib 12%
• Phosphatidylinositol-4,5-bisphosphate 3-Kinase 12%
• MED1 12%
• Peroxisome Proliferator Activated Receptor Binding Protein 12%
• Liquid Biopsy 12%